Rhythm Biosciences ColoSTAT authorised for sale in New Zealand

Latest News

Cancer diagnostics technology company, Rhythm Biosciences (ASX:RHY), has secured authorisation for ColoSTAT in New Zealand.

The country's regulator Medsafe has registered ColoSTAT as a blood test to detect colorectal cancer.

The regulatory milestone means that Rhythm can market ColoSTAT for sale in New Zealand and commence partnership discussions.

Rhythm CEO and managing director Glenn Gilbert said, “Rhythm is pleased to expand its international regulatory approval footprint into New Zealand which enables the Company to commence marketing and sales activities for ColoSTAT.

"Bowel cancer is the second highest cause of cancer death in New Zealand and a growing issue with 1 in 10 now diagnosed under the age of 50.

"ColoSTAT is a simple blood test which has the potential to make a material impact on health outcomes through mass screening for higher participation to achieve early diagnosis. We look forward to working with the Ministry of Health’s National Screening Unit to enhance New Zealand’s National Bowel Screening Programme.”